Russell Investments Group
SPRY icon

Russell Investments Group’s ARS Pharmaceuticals SPRY Stock Holding History

Russell Investments Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.3K Sell
5,140
-665
-11% -$6.37K ﹤0.01% 3383
2025
Q4 		$67.6K Sell
5,805
-863
-13% -$8.39K ﹤0.01% 3188
2025
Q3 		$67K Buy
6,668
+4,427
+198% +$63.5K ﹤0.01% 3163
2025
Q2 		$39.1K Buy
2,241
+228
+11% +$3.29K ﹤0.01% 3038
2025
Q1 		$25.3K Buy
2,013
+1,096
+120% +$13.2K ﹤0.01% 3058
2024
Q4 		$9.67K Sell
917
-30,760
-97% -$431K ﹤0.01% 3139
2024
Q3 		$459K Buy
31,677
+2,690
+9% +$32K ﹤0.01% 2302
2024
Q2 		$247K Buy
28,987
+23,090
+392% +$205K ﹤0.01% 2425
2024
Q1 		$60.3K Buy
+5,897
New +$44K ﹤0.01% 2644
2023
Q2 		– Sell
-7,476
Closed -$48.7K – 3523
2023
Q1 		$48.7K Sell
7,476
-160
-2% -$1.23K ﹤0.01% 2717
2022
Q4 		$65.1K Buy
7,636
+638
+9% +$4.14K ﹤0.01% 2718
2022
Q3 		$36K Sell
6,998
-1,414
-17% -$6.97K ﹤0.01% 2768
2022
Q2 		$35K Buy
+8,412
New +$29.3K ﹤0.01% 2755

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Russell Investments Group's SPRY Position: Q1 2026 in Review

Russell Investments Group reduced its ARS Pharmaceuticals (SPRY) stake by 11% in Q1 2026, selling an estimated $6.37K and leaving 5,140 shares worth $41.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3383.

Russell Investments Group first reported a position in SPRY in Q2 2022 and has held it in 13 quarters since. The position peaked at $459K in Q3 2024. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Russell Investments Group held 5,140 shares of ARS Pharmaceuticals worth $41.3K as of Q1 2026.
  • Russell Investments Group sold 665 ARS Pharmaceuticals shares in Q1 2026, an estimated $6.37K.
  • ARS Pharmaceuticals made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #3383 holding.
  • Russell Investments Group first reported a position in ARS Pharmaceuticals in Q2 2022 and has held it in 13 quarters since.
  • Russell Investments Group's ARS Pharmaceuticals position peaked at $459K in Q3 2024.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.